<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">detinf</journal-id><journal-title-group><journal-title xml:lang="ru">ДЕТСКИЕ ИНФЕКЦИИ</journal-title><trans-title-group xml:lang="en"><trans-title>CHILDREN INFECTIONS</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-8107</issn><issn pub-type="epub">2618-8139</issn><publisher><publisher-name>Association of Pediatricians and Infection Disease doctors</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.22627/2072-8107-2025-24-4-20-25</article-id><article-id custom-type="elpub" pub-id-type="custom">detinf-1112</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Особенности липидного обмена у детей с хроническим гепатитом С</article-title><trans-title-group xml:lang="en"><trans-title>Characteristics of lipid metabolism in children with chronic hepatitis C</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7836-1883</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Никифорова</surname><given-names>А. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Nikiforova</surname><given-names>A. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Никифорова Александра Олеговна, младший научный сотрудник научно-исследовательского отдела вирусных гепатитов и заболеваний печени</p><p>Санкт-Петербург   </p></bio><bio xml:lang="en"><p>Saint-Petersburg </p></bio><email xlink:type="simple">alexa-nikiforova@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4509-5352</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Грешнякова</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Greshnyakova</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Грешнякова Вера Александровна, к.м.н., руководитель научно-исследовательского отдела вирусных гепатитов и заболеваний печени </p><p>Санкт-Петербург   </p></bio><bio xml:lang="en"><p>Saint-Petersburg </p></bio><email xlink:type="simple">veramamayeva@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3679-1874</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Жданов</surname><given-names>К. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Zhdanov</surname><given-names>K. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Жданов Константин Валерьевич, директор научно-клинического центра  </p><p>Санкт-Петербург   </p></bio><bio xml:lang="en"><p>Saint-Petersburg </p></bio><email xlink:type="simple">zhdanovkv@rambler.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7890-733X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Горячева</surname><given-names>Л. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Goryacheva</surname><given-names>L. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Горячева Лариса Георгиевна, ведущий научный сотрудник отдела вирусных гепатитов </p><p>Санкт-Петербург   </p></bio><bio xml:lang="en"><p>Saint-Petersburg </p></bio><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральный научно-клинический центр инфекционных болезней</institution></aff><aff xml:lang="en"><institution>Federal Research and Clinical Center for Infectious Diseases</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Федеральный научно-клинический центр инфекционных болезней; Санкт-Петербургский государственный педиатрический медицинский университет; Санкт-Петербургский государственный университет</institution></aff><aff xml:lang="en"><institution>Federal Research and Clinical Center for Infectious Diseases; Saint-Petersburg State Pediatric Medical University,</institution></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Федеральный научно-клинический центр инфекционных болезней; Санкт-Петербургский государственный университет</institution></aff><aff xml:lang="en"><institution>Federal Research and Clinical Center for Infectious Diseases</institution></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>Федеральный научно-клинический центр инфекционных болезней; Санкт-Петербургский государственный педиатрический медицинский университет</institution></aff><aff xml:lang="en"><institution>Federal Research and Clinical Center for Infectious Diseases; Saint-Petersburg State Pediatric Medical University,</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>27</day><month>11</month><year>2025</year></pub-date><volume>24</volume><issue>4</issue><fpage>20</fpage><lpage>25</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Никифорова А.О., Грешнякова В.А., Жданов К.В., Горячева Л.Г., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Никифорова А.О., Грешнякова В.А., Жданов К.В., Горячева Л.Г.</copyright-holder><copyright-holder xml:lang="en">Nikiforova A.O., Greshnyakova V.A., Zhdanov K.V., Goryacheva L.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://detinf.elpub.ru/jour/article/view/1112">https://detinf.elpub.ru/jour/article/view/1112</self-uri><abstract><p>Цель исследования: проанализировать состояние липидного обмена, состава тела, структуры паренхимы печени у детей с хроническим гепатитом С (ХГС). Методы. Группа исследования — 63 ребенка с ХГС в возрасте 3—17 лет без сопутствующей эндокринной патологии, обследованных в 2022—2024 г. в ДНКЦИБ. Группа контроля — 37 здоровых детей в возрасте 9—17 лет. Всем проведена антропометрия, лабораторное обследование (ПЦР РНК HCV, липидограмма), эластография печени с оценкой стеатоза. Результаты. У детей с ХГС достоверно чаще отмечается гиполипидемия в виде снижения уровней общего холестерина и липопротеидов низкой плотности (ЛПНП) (p &lt; 0,05), в то время как у здоровых детей — снижение липопротеидов высокой плотности (ЛПВП) и повышение коэффициента атерогенности (p &lt; 0,05). В группе исследования отклонения в показателях липидного обмена были обнаружены у 39,6% детей, при этом большинство (64%) имели «здоровый вес». Повышение уровня холестерина не-ЛПВП чаще регистрировалось у детей со «здоровым весом» и было ассоциировано с 1 и 2 (не-3) генотипами вируса (p &lt; 0,05). Практически у половины (43,2%) детей с ХГС выявлен стеатоз печени, ассоциированный с не-3 генотипом вируса (p &lt; 0,05). У детей с ХГС без ожирения достоверно чаще формируется стеатоз по сравнению с контрольной группой (p &lt; 0,05). Выводы. У детей с ХГС обнаружены вирус-индуцированные изменения показателей липидного обмена независимо от наличия или отсутствия избыточной массы тела (МТ), ассоциированные с не-3 генотипом вируса. Гиполипидемия достоверно связана с ВГС. Стеатоз печени достоверно чаще формируется у детей с ХГС без избытка МТ по сравнению со здоровыми детьми, что дополнительно подтверждает влияние вируса на липидный профиль.</p></abstract><trans-abstract xml:lang="en"><p>The Aim: To analyze the state of lipid metabolism, body composition, and liver parenchyma structure in children with chronic hepatitis C (СHC). Methods. The study group consisted of 63 children with СHC aged 3—17 years without concomitant endocrine pathology, who were examined in 2022—2024 at the NCCIB. The control group consisted of 37 healthy children aged 9—17 years. All underwent anthropometry, laboratory examination (HCV RNA PCR, lipidogram), liver elastography with assessment of steatosis. Results. Children with СHC are significantly more likely to have hypolipidemia in the form of a decrease in total cholesterol and low-density lipoprotein (LDL) levels (p &lt; 0.05), while in healthy children there is a decrease in high-density lipoproteins (HDL) and an increase in the coefficient of atherogenicity (p &lt; 0.05). In the study group, abnormalities in lipid metabolism were found in 39.6% of children, while the majority (64%) had a «healthy weight». An increase in the level of non-HDL cholesterol was more often recorded in children with a «healthy weight» and was associated with genotypes 1 and 2 (non-3) of the virus (p &lt; 0.05). Almost half (43.2%) of children with СHC had liver steatosis associated with the non-3 genotype of the virus (p &lt; 0.05). Children with СHC without obesity are significantly more likely to develop steatosis compared with the control group (p &lt; 0.05). Conclusions. Virus-induced changes in lipid metabolism parameters, regardless of the presence or absence of overweight, associated with the non-3 genotype of the virus, were found in children with СHC. Hypolipidemia is significantly associated with HCV. Liver steatosis is significantly more common in children with СHC without excess weight compared to healthy children, which further confirms the effect of the virus on the lipid profile.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>метаболические нарушения при ХГС</kwd><kwd>нарушения липидного обмена при гепатите С</kwd><kwd>дислипидемия</kwd><kwd>гиполипидемия</kwd><kwd>стеатоз печени у детей с гепатитом С</kwd><kwd>эластография печени при гепатите С</kwd></kwd-group><kwd-group xml:lang="en"><kwd>metabolic disorders in HCV-infection</kwd><kwd>lipid metabolism disorders in children with chronic hepatitis C</kwd><kwd>dyslipidemia</kwd><kwd>hypolipidemia</kwd><kwd>liver steatosis in children with chronic hepatitis C</kwd><kwd>steatosis in children with hepatitis C</kwd><kwd>liver elastography in hepatitis C</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">ВОЗ бьет тревогу: вирусные гепатиты ежедневно уносят 3500 жизней [Электронный ресурс] ВОЗ. URL: https://www.who.int/ru/news/item/ 09-04-2024-who-sounds-alarm-on-viral-hepatitis-infections-claiming-3500-lives-each-day [дата обращения 20.07.2025].</mixed-citation><mixed-citation xml:lang="en">WHO sounds the alarm: viral hepatitis claims 3,500 lives every day [E`lektronny`j resurs]. VOZ. URL: https://www.who.int/ru/news/item/09-04-2024-who-sounds-alarm-on-vi-ral-hepatitis-infections-claiming-3500-liveseach-day [data obrashheniya 20.07.2025]. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Granot E, Sokal EM. Hepatitis C Virus in Children: Deferring Treatment in Expectation of Direct-Acting Antiviral Agents. Isr Med Assoc J. 2015 Nov; 17(11):707-11.</mixed-citation><mixed-citation xml:lang="en">Granot E, Sokal EM. Hepatitis C Virus in Children: Deferring Treatment in Expectation of Direct-Acting Antiviral Agents. Isr Med Assoc J. 2015 Nov; 17(11):707—11.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Chilaka VN, Konje JC. Viral Hepatitis in pregnancy. Eur J Obstet Gynecol Reprod Biol. 2021 Jan; 256:287—296. doi:10.1016/j.ejogrb.2020.11.052.</mixed-citation><mixed-citation xml:lang="en">Chilaka VN, Konje JC. Viral Hepatitis in pregnancy. Eur J Obstet Gynecol Reprod Biol. 2021 Jan; 256:287—296. doi:10.1016/j.ejogrb.2020.11.052.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Chaudhari R, Fouda S, Sainu A, Pappachan JM. Metabolic complications of hepatitis C virus infection. World J Gastroenterol. 2021 Apr 7; 27 (13):1267—1282. doi: 10.3748/wjg.v27.i13.1267.</mixed-citation><mixed-citation xml:lang="en">Chaudhari R, Fouda S, Sainu A, Pappachan JM. Metabolic complications of hepatitis C virus infection. World J Gastroenterol. 2021 Apr 7; 27(13):1267—1282. doi: 10.3748/wjg.v27.i13.1267.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Sheridan DA, Shawa IT, Thomas EL, Felmlee DJ, et al. Infection with the hepatitis C virus causes viral genotype-specific differences in cholesterol metabolism and hepatic steatosis. Scientific reports. 1 Apr. 2022; 12(1):5562. doi:10.1038/s41598-022-09588-w.</mixed-citation><mixed-citation xml:lang="en">Sheridan DA, Shawa IT, Thomas EL, Felmlee DJ, et al. Infection with the hepatitis C virus causes viral genotype-specific differences in cholesterol metabolism and hepatic steatosis. Scientific reports. 1 Apr. 2022; 12(1):5562. doi:10.1038/s41598-022-09588-w.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Elgretli W, Chen T, Kronfli N, Sebastiani G. Hepatitis C Virus-Lipid Interplay: Pathogenesis and Clinical Impact. Biomedicines. 19 Jan. 2023; 11,2 271. doi:10.3390/biomedicines11020271</mixed-citation><mixed-citation xml:lang="en">Elgretli W, Chen T, Kronfli N, Sebastiani G. Hepatitis C Virus-Lipid Interplay: Pathogenesis and Clinical Impact. Biomedicines. 19 Jan. 2023; 11,2 271. doi:10.3390/biomedicines11020271</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Adinolfi LE, Rinaldi L, Guerrera B, Restivo L, Marrone A, Giordano M, Zampino R. NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. Int J Mol Sci. 2016 May 25; 17(6):803. doi: 10.3390/ijms17060803.</mixed-citation><mixed-citation xml:lang="en">Adinolfi LE, Rinaldi L, Guerrera B, Restivo L, Marrone A, Giordano M, Zampino R. NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. Int J Mol Sci. 2016 May 25; 17(6):803. doi: 10.3390/ijms17060803.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Жданов К.В., Карякин С.С., Козлов К.В., Гусев Д.А., и др. Хронический гепатит С и неалкогольная жировая болезнь печени. Основные аспекты патогенеза. Вестник Российской военно-медицинской академии. 2018; 20(1): 216—221. doi: 10.17816/brmma12326.</mixed-citation><mixed-citation xml:lang="en">Zhdanov K.V., Karyakin S.S., Kozlov K.V., Gusev D.A.,et al. Chronic hepatitis C and non-alcoholic fatty liver disease. Key aspects of pathogenesis. Vestnik Rossijskoj voenno-medicinskoj akademii. 2018; 20(1):216—221. (In Russ.) doi: 10.17816/brmma12326]</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">d'Avigdor WMH, Budzinska MA, Lee M, Lam R, et al. Virus Genotype-Dependent Transcriptional Alterations in Lipid Metabolism and Inflammation Pathways in the Hepatitis C Virus-infected. Liver. Sci Rep. 2019; 9:10596. https://doi.org/10.1038/s41598-019-46664-0</mixed-citation><mixed-citation xml:lang="en">d'Avigdor WMH, Budzinska MA, Lee M, Lam R, et al. Virus Genotype-Dependent Transcriptional Alterations in Lipid Metabolism and Inflammation Pathways in the Hepatitis C Virus-infected. Liver. Sci Rep. 2019; 9:10596. https://doi.org/10.1038/s41598-019-46664-0</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Никитин В.Ю., Сухина И.А., Яременко М.В., Жданов К.В., и др. Влияние факторов метаболического риска на состояние иммунитета больных ХГС при проведении противовирусной терапии. Медицинская иммунология. 2017; 19 (S): 220. 11. Диабет [Электронный ресурс]. ВОЗ. URL: https://www.who.int/ru/news-room/fact-sheets/detail/diabetes [дата обращения 20.07.2025].</mixed-citation><mixed-citation xml:lang="en">Nikitin V.Yu., Suhina I.A., Yaremenko M.V., Zhdanov K.V., et al. Analysis of metabolic risk factors on the immune status of patients with chronic hepatitis C during antiviral therapy. Medicinskaya Immunologiya. 2017; 19(S):220. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ожирение и избыточная масса тела [Электронный ресурс]. ВОЗ. https://www.who.int/ru/news-room/fact-sheets/detail/obesity-andoverweight [дата обращения 28.07.2025].</mixed-citation><mixed-citation xml:lang="en">Diabet [E`lektronny`j resurs]. VOZ. URL: https://www.who.int/ru/newsroom/fact-sheets/detail/diabetes [data obrashheniya 20.07.2025]. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet. 2017 Dec 16; 390(10113):2627—2642. doi: 10.1016/S0140-6736(17)32129-3.</mixed-citation><mixed-citation xml:lang="en">Obesity and overweight [E`lektronny`j resurs]. VOZ. https://www.who.int/ru/news-room/fact-sheets/detail/obesity-andoverweight [data obrashheniya 28.07.2025]. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Siphepho PY, Liu YT, Shabangu CS, Huang JF, Huang CF, Yeh ML, Yu ML, Wang SC. The Impact of Steatosis on Chronic Hepatitis C Progression and Response to Antiviral Treatments. Biomedicines. 2021 Oct 17; 9(10):1491. doi: 10.3390/biomedicines9101491.</mixed-citation><mixed-citation xml:lang="en">Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet. 2017 Dec 16; 390(10113):2627—2642. doi: 10.1016/S0140-6736(17)32129-3.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Жданов К.В., Козлов К.В., Сукачев В.С., Захаренко С.М. и др. Элиминация HCV-инфекции: история с продолжением. Журнал инфектологии. 2018; 10(4):6—13.doi: 10.22625/2072-6732-2018-10-4-6-13.</mixed-citation><mixed-citation xml:lang="en">Siphepho PY, Liu YT, Shabangu CS, Huang JF, Huang CF, Yeh ML, Yu ML, Wang SC. The Impact of Steatosis on Chronic Hepatitis C Progression and Response to Antiviral Treatments. Biomedicines. 2021 Oct 17; 9(10):1491. doi: 10.3390/biomedicines9101491.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Sidorkiewicz M. Hepatitis C Virus Uses Host Lipids to Its Own Advantage. Metabolites. 2021 Apr 27; 11(5):273. doi: 10.3390/metabo11050273.</mixed-citation><mixed-citation xml:lang="en">Zhdanov K.V., Kozlov K.V., Sukachev V.S., Zaxarenko S.M., et al. Elimination of HCV infection: a continuing story. Zhurnal Infektologii. 2018; 10(4):6—13. (In Russ.) doi: 10.22625/2072-6732-2018-10-4-6-13</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Mancone C, Montaldo C, Santangelo L, Di Giacomo C, et al. Ferritin heavy chain is the host factor responsible for HCV-induced inhibition of apoB-100 production and is required for efficient viral infection. J Proteome Res. 2012; 11:2786-2797.</mixed-citation><mixed-citation xml:lang="en">Sidorkiewicz M. Hepatitis C Virus Uses Host Lipids to Its Own Advantage. Metabolites. 2021 Apr 27; 11(5):273. doi: 10.3390/metabo11050273.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Жданов К.В., Козлов К.В., Сукачев В.С. Гепатит С и неалкогольная жировая болезнь печени у пациентов с ВИЧ-инфекцией. ВИЧ-инфекция и иммуносупрессии. 2017; 9(1):36—42. doi: 10.22328/2077-9828-2017-9-1-36-42.</mixed-citation><mixed-citation xml:lang="en">Mancone C, Montaldo C, Santangelo L, Di Giacomo C, et al. Ferritin heavy chain is the host factor responsible for HCV-induced inhibition of apoB-100 production and is required for efficient viral infection. J Proteome Res. 2012; 11:2786-2797.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Gonzalez-Aldaco K, Torres-Reyes LA, Ojeda-Granados C, Leal-Mercado L, Roman S, Panduro A. Metabolic Dysfunction-Associated Steatotic Liver Disease in Chronic Hepatitis C Virus Infection: From Basics to Clinical and Nutritional Management. Clin Pract. 2024 Nov 24; 14(6):2542—2558. doi: 10.3390/clinpract14060200.</mixed-citation><mixed-citation xml:lang="en">Zhdanov K.V., Kozlov K.V., Sukachev V.S. Hepatitis C and non-alcoholic fatty liver disease in patients with HIV infection. VICH-infekciya i Immunosupressii. 2017; 9(1):36—42.(In Russ.) doi: 10.22328/2077-9828-2017-9-1-36-42</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Жданов К.В., Яременко М.В., Козлов К.В., Сукачев В.С., и др. Неинвазивная диагностика стеатоза печени у пациентов с ХГС. Нерешенные вопросы этиотропной терапии актуальных инфекций: Материалы Всероссийской ежегодной научно-практической конференции, Санкт-Петербург, 05—06 декабря 2022 года. Санкт-Петербург: Санкт-Петербургская общественная организация «Человек и его здоровье». 2022: 42—52.</mixed-citation><mixed-citation xml:lang="en">Gonzalez-Aldaco K, Torres-Reyes LA, Ojeda-Granados C, Leal-Mercado L, Roman S, Panduro A. Metabolic Dysfunction-Associated Steatotic Liver Disease in Chronic Hepatitis C Virus Infection: From Basics to Clinical and Nutritional Management. Clin Pract. 2024 Nov 24; 14(6):2542—2558. doi: 10.3390/clinpract14060200.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Яременко М.В., Жданов К.В., Захаренко., Иванов А.М., и др. Оценка показателей липидного обмена у больных хроническим гепатитом С до и после ПВТ. Нерешенные вопросы этиотропной терапии актуальных инфекций: Материалы Всероссийской научно-практической конференции, Санкт-Петербург, 08—09 декабря 2016 года. Санкт-Петербург: Санкт-Петербургская общественная организация «Человек и его здоровье». 2016: 70.</mixed-citation><mixed-citation xml:lang="en">Zhdanov K.V., Yaremenko M.V., Kozlov K.V., Sukachev V.S., et al. Non-invasive diagnosis of liver steatosis in patients with chronic hepatitis C. Nereshenny`e voprosy` e`tiotropnoj terapii aktual`ny`x infekcij: Materialy` Vserossijskoj ezhegodnoj nauchno-prakticheskoj konferencii, Sankt-Peterburg, 05— 06 dekabrya 2022. Sankt-Peterburg: Sankt-Peterburgskaya obshhestvennaya organizaciya «Chelovek i ego zdorov`e». 2022:42—52. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Yaremenko M.V., Zhdanov K.V., Zaharenko., Ivanov A.M., et al. Evaluation of lipid metabolism parameters in patients with chronic hepatitis C before and after antiviral therapy. Nereshenny`e voprosy` e`tiotropnoj terapii aktual`ny`x infekcij: Materialy` Vserossijskoj nauchno-prakticheskoj konferencii, Sankt-Peterburg, 08—09 dekabrya 2016. Sankt-Peterburg: Sankt-Peterburgskaya obshhestvennaya organizaciya «Chelovek i ego zdorov`e». 2016:70. (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Yaremenko M.V., Zhdanov K.V., Zaharenko., Ivanov A.M., et al. Evaluation of lipid metabolism parameters in patients with chronic hepatitis C before and after antiviral therapy. Nereshenny`e voprosy` e`tiotropnoj terapii aktual`ny`x infekcij: Materialy` Vserossijskoj nauchno-prakticheskoj konferencii, Sankt-Peterburg, 08—09 dekabrya 2016. Sankt-Peterburg: Sankt-Peterburgskaya obshhestvennaya organizaciya «Chelovek i ego zdorov`e». 2016:70. (In Russ.)</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
